恩格列净降低2型糖尿病合并冠心病患者的心肌细胞外容积
本研究为EMPA-HEART CardioLink-6试验的预设亚组分析,97例2型糖尿病合并冠心病患者随机接受恩格列净10 mg每日一次或安慰剂治疗6个月,74例纳入分析(恩格列净组39例,安慰剂组35例)。心脏磁共振显示,与安慰剂相比,恩格列净组6个月时细胞外容积(ECV)降低(校正差值-1.40%,95%CI -2.60至-0.14%,p=0.03),iECV降低(校正差值-1.5 ml/m2,95%CI -2.6至-0.5 ml/m2,p=0.006),iICV呈降低趋势(校正差值-1.7 ml/m2,95%CI -3.8至0.3 ml/m2,p=0.09),MMP-2和sST2无变化。
要点
- 2型糖尿病合并冠心病患者基线ECV升高:恩格列净组29.6±4.6%,安慰剂组30.6±4.8%。
- 恩格列净10 mg每日一次治疗6个月较安慰剂降低ECV(校正差值-1.40%,95%CI -2.60至-0.14%,p=0.03)。
- 恩格列净降低iECV(校正差值-1.5 ml/m2,95%CI -2.6至-0.5 ml/m2,p=0.006),iICV呈降低趋势但未达统计学显著。
核心结论
- 在2型糖尿病合并冠心病患者中,恩格列净治疗6个月降低ECV、iECV和左心室质量指数(LVMi)。
- 恩格列净对MMP-2和sST2无影响。
- 恩格列净导致逆向重构的机制需要进一步研究。
研究设计与样本
- 本研究为EMPA-HEART CardioLink-6试验的预设亚组分析,该试验将97例参与者随机分配至恩格列净10 mg每日一次组或安慰剂组治疗6个月。
- 分析纳入74例参与者的数据:恩格列净组39例,安慰剂组35例。
- 主要结局为经心脏磁共振(CMR)测定的基线至6个月左心室ECV变化。
- 其他结局包括LVMi、标化的细胞内 compartment 容积(iICV)、标化的细胞外 compartment 容积(iECV)以及纤维化生物标志物可溶性肿瘤抑制因子(sST2)和基质金属蛋白酶(MMP)-2的变化。
关键影像表现/征象
- 基线ECV在恩格列净组为29.6±4.6%,在安慰剂组为30.6±4.8%,均升高。
诊断标准与关键数值
- 主要结局ECV:恩格列净组较安慰剂组校正差值为-1.40%(95%CI -2.60至-0.14%,p=0.03)。
- iECV:恩格列净组较安慰剂组校正差值为-1.5 ml/m2(95%CI -2.6至-0.5 ml/m2,p=0.006)。
- iICV:恩格列净组较安慰剂组校正差值为-1.7 ml/m2(95%CI -3.8至0.3 ml/m2,p=0.09),呈降低趋势但未达统计学显著。
- MMP-2和sST2:恩格列净组与安慰剂组相比无影响。
临床应用与阅片要点
- 在2型糖尿病合并冠心病患者中,恩格列净治疗6个月可降低CMR测定的心肌ECV、iECV和LVMi,阅片时可关注这些影像学指标的变化。
- 恩格列净对纤维化生物标志物MMP-2和sST2无影响,提示ECV降低的机制可能不完全通过这些标志物反映。
局限性
- 原文结论指出,需要进一步研究恩格列净导致逆向重构的机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study sought to evaluate the effects of empagliflozin on extracellular volume (ECV) in individuals with type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD).
BACKGROUND: Empagliflozin has been shown to reduce left ventricular mass index (LVMi) in patients with T2DM and CAD. The effects on myocardial ECV are unknown.
METHODS: This was a prespecified substudy of the EMPA-HEART (Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes) CardioLink-6 trial in which 97 participants were randomized to receive empagliflozin 10 mg daily or placebo for 6 months. Data from 74 participants were included: 39 from the empagliflozin group and 35 from the placebo group. The main outcome was change in left ventricular ECV from baseline to 6 months determined by cardiac magnetic resonance (CMR). Other outcomes included change in LVMi, indexed intracellular compartment volume (iICV) and indexed extracellular compartment volume (iECV), and the fibrosis biomarkers soluble suppressor of tumorgenicity (sST2) and matrix metalloproteinase (MMP)-2.
RESULTS: Baseline ECV was elevated in the empagliflozin group (29.6 ± 4.6%) and placebo group (30.6 ± 4.8%). Six months of empagliflozin therapy reduced ECV compared with placebo (adjusted difference: -1.40%; 95% confidence interval [CI]: -2.60 to -0.14%; p = 0.03). Empagliflozin therapy reduced iECV (adjusted difference: -1.5 ml/m2; 95% CI: -2.6 to -0.5 ml/m2; p = 0.006), with a trend toward reduction in iICV (adjusted difference: -1.7 ml/m2; 95% CI: -3.8 to 0.3 ml/m2; p = 0.09). Empagliflozin had no impact on MMP-2 or sST2.
CONCLUSIONS: In individuals with T2DM and CAD, 6 months of empagliflozin reduced ECV, iECV, and LVMi. No changes in MMP-2 and sST2 were seen. Further investigation into the mechanisms by which empagliflozin causes reverse remodeling is required. (Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes [EMPA-HEART]; NCT02998970).
引用
- Mason T, Coelho-Filho OR, Verma S, et al. Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease. JACC Cardiovasc Imaging. 2021. PMID: 33454272. doi:10.1016/j.jcmg.2020.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。